Loss of lineage fidelity underpins KRAS drug resistance in mice
Acquired resistance limits durable clinical responses to KRAS inhibition in Kras-mutant lung cancer, according to a Nature Genetics paper. Working with genetically engineered mouse models, the authors demonstrated that lineage fidelity modulates drug-tolerant residual disease and distinct trajectories of therapeutic resistance. This loss also dictates dependence on oncogenic KRAS. The work was in mice.
The results help clarify why KRAS-mutant lung cancer develops resistance to inhibitors, though mouse models do not provide clinical evidence.
Written by the Genomes desk from the primary source cited and linked above and checked against it. Research use only; not medical advice. Corrections: [email protected].